SCHEMBL8171384

SCHEMBL8171384

C/C(=C\C(=O)N1CCCCC1)c1cc(-c2ccccc2F)cs1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ LTB4R Q15722 1/20 0.39
▸ LTB4R2 Q9NPC1 1/20 0.39
▸ GRIN2B Q13224 5/20 0.38
▸ ALDH1A1 P00352 6/20 0.37
▸ POLB P06746 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 2/20 0.35
▸ RIPK1 Q13546 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ HTR3A P46098 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603493 1.00 NPC1 (0.39) NPC1RAB9ALTB4RLTB4R2GRIN2B
SCHEMBL3603495 1.00 NPC1 (0.39) NPC1RAB9ALTB4RLTB4R2GRIN2B
SCHEMBL3607182 0.80 ALDH1A1 (0.53) NPC1RAB9AGRIN2BALDH1A1POLB
SCHEMBL8164614 0.80 ALDH1A1 (0.53) NPC1RAB9AGRIN2BALDH1A1POLB
SCHEMBL3607180 0.78 ALDH1A1 (0.39) NPC1RAB9AGRIN2BALDH1A1POLB
SCHEMBL7079303 0.73 HDAC6 (0.45) ALDH1A1MAPTMEN1KMT2ANPSR1
SCHEMBL3180560 0.71 NPC1 (0.47) NPC1RAB9AGRIN2BALDH1A1MEN1
SCHEMBL3602330 0.70 PREP (0.43) NPC1RAB9AGRIN2B
SCHEMBL3602332 0.70 PREP (0.43) NPC1RAB9AGRIN2B
SCHEMBL8176875 0.64 ALDH1A1 (0.52) NPC1RAB9AALDH1A1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304438-B2 Heteroarylacrylamides and their use as pharmaceuticals SANOFI (FR) 2012-11-06 — — US disclosed
US-20100016272-A1 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-01-21 — — US disclosed
WO-2008074413-A2 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE SANOFI-AVENTIS (FR) 2008-06-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016272-A1 HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS NOS3, PTGIS, NOS1 NPC1 4260/4885RAB9A 1874/4885LTB4R 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback